ADE

American Society of Pharmacovigilance Amplifies Coordinated Efforts on Third Annual National Adverse Drug Event Day

Retrieved on: 
Wednesday, March 20, 2024

HOUSTON, March 20, 2024 /PRNewswire/ -- Almost one million Americans have died of adverse drug events, many avoidable, in the three year history of National Adverse Drug Event (ADE) Day.

Key Points: 
  • HOUSTON, March 20, 2024 /PRNewswire/ -- Almost one million Americans have died of adverse drug events, many avoidable, in the three year history of National Adverse Drug Event (ADE) Day.
  • The American Society of Pharmacovigilance (ASP) is proud to spotlight the unified efforts of healthcare organizations nationwide to address this public health crisis.
  • The society encourages individuals and professionals alike to visit fourthcause.org to deepen their understanding and participation in this critical cause.
  • National ADE Day has become a cornerstone event for rallying healthcare providers, patients, and policymakers around the vital issue of medication safety.

NetEase Cloud Music Takes the Stage at ADE 2023: Debut as Speaker on China's Dance Music Trends

Retrieved on: 
Friday, October 20, 2023

HANGZHOU, China, Oct. 20, 2023 /PRNewswire/ -- Cloud Music Inc. (HKEX: 9899, "NetEase Cloud Music" or the "Company"), a well-known online music platform featuring a vibrant content community, participated for the first time as an ADE Pro speaker at ADE 2023, sharing insights and opportunities in China's dance music industry.

Key Points: 
  • HANGZHOU, China, Oct. 20, 2023 /PRNewswire/ -- Cloud Music Inc. (HKEX: 9899, "NetEase Cloud Music" or the "Company"), a well-known online music platform featuring a vibrant content community, participated for the first time as an ADE Pro speaker at ADE 2023, sharing insights and opportunities in China's dance music industry.
  • "Dance music ranks among the Top 3 most streamed genres on NetEase Cloud Music.
  • As one of the largest dance music platforms in China, we have strategically partnered with the world's top dance music labels to bring their expanding, high-quality content to music lovers in China," said Vivian Wei, Vice President of Copyrights, NetEase Cloud Music.
  • "We also provide musicians with music production, A&R, and promotion support, nurturing their careers while benefiting the dance music industry in the long run."

DoseMe Selected as a Pharma 2023 Innovation Award Winner

Retrieved on: 
Wednesday, September 27, 2023

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) today announced its DoseMe Analytics platform was named a winner of the Pharma Innovation Awards.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) today announced its DoseMe Analytics platform was named a winner of the Pharma Innovation Awards.
  • Pharma Manufacturing , an Endeavor Business Media brand, annually recognizes technologies contributing to advancements in risk reduction, product quality improvement, and manufacturing efficiency.
  • The Pharma Innovation Awards are a tribute to those who listen to the needs of the market and their customers, and as a result, have distinguished themselves as leaders in pharma equipment and technology.
  • “We are honored to be selected along with 12 other incredibly valuable tools that help pharma companies to develop innovative, lifesaving medicines,” stated Paul Edwards, CEO of DoseMe.

SAS Energy Forecasting improves utilities' response to extreme conditions

Retrieved on: 
Tuesday, September 12, 2023

LAS VEGAS, Sept. 12, 2023 /PRNewswire/ -- SAS EXPLORE -- Facing increased uncertainty from extreme weather, utility companies must accurately predict customer demand and better manage infrastructure. All this to ensure homes, stores, factories, schools and farms have the electricity they need.

Key Points: 
  • SAS, the leader in AI and analytics, provides SAS® Energy Forecasting Cloud to help utilities reliably serve their customers through improved planning and operations.
  • SAS Energy Forecasting Cloud is the first SAS solution leveraging SAS App Factory, a new SAS Viya® offering previewed at SAS Explore and generally available in 2024.
  • With the new SAS Energy Forecasting Cloud, SAS is providing the power of AI and advanced analytics as a service.
  • SAS Energy Forecasting and SAS Energy Forecasting Cloud help them automatically track model accuracy and easily update models as conditions change – spanning very short-term to long-term horizons.

IRONSCALES Announces Launch of GPT-powered Phishing Simulation Testing and Accidental Data Exposure Capabilities, Transforming Inbound and Outbound Email Protection for Enterprises

Retrieved on: 
Wednesday, August 9, 2023

In addition, IRONSCALES announced a new accidental data exposure (ADE) capability, which alerts employees when sending potentially sensitive information, thereby adding a critical layer of outbound email protection to its best-in-class inbound security.

Key Points: 
  • In addition, IRONSCALES announced a new accidental data exposure (ADE) capability, which alerts employees when sending potentially sensitive information, thereby adding a critical layer of outbound email protection to its best-in-class inbound security.
  • GPT-powered PST is the second generative AI-enabled development to be added to IRONSCALES’ suite of generative AI apps for email security.
  • Every spear phishing simulation message is crafted utilizing PhishLLM, IRONSCALES' proprietary LLM model that has been trained on millions of data points from the IRONSCALES community.
  • Accidental Data Exposure (ADE): Increase employee awareness and safeguard against the inadvertent transfer of sensitive data.

Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate

Retrieved on: 
Tuesday, June 6, 2023

No treatment-related serious adverse events were reported, and the majority of adverse events were mild and transient.

Key Points: 
  • No treatment-related serious adverse events were reported, and the majority of adverse events were mild and transient.
  • From a safety perspective, both doses were considered acceptable for use in further trials.
  • These data demonstrate that our product platform has an acceptable safety profile and successfully mobilises viral-specific CD8+ T cells, which may elicit broad and long-term immune memory.
  • Follow-up of trial participants took place over a six-month period following first injection.

Synapse Announces Launch of Data Extraction Tool for Universal Analytics

Retrieved on: 
Thursday, May 18, 2023

NEWTON, Mass., May 18, 2023 /PRNewswire-PRWeb/ -- Synapse, a leading performance marketing firm, announced today the launch of their new data extraction tool, ADE (Analytics Data Extractor). ADE is currently the only known tool that can extract completely unsampled data from Universal Analytics (UA) across large data sets.

Key Points: 
  • Synapse, a leading performance marketing firm, announced today the launch of their new data extraction tool, ADE (Analytics Data Extractor).
  • ADE is currently the only known tool that can extract completely unsampled data from Universal Analytics (UA) across large data sets.
  • NEWTON, Mass., May 18, 2023 /PRNewswire-PRWeb/ -- Synapse, a leading performance marketing firm, announced today the launch of their new data extraction tool, ADE (Analytics Data Extractor).
  • ADE is currently the only known tool that can extract completely unsampled data from Universal Analytics (UA) across large data sets.

Ellington Residential Mortgage REIT Reports First Quarter 2023 Results

Retrieved on: 
Thursday, May 11, 2023

Ellington Residential Mortgage REIT (NYSE: EARN) (the "Company") today reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • Ellington Residential Mortgage REIT (NYSE: EARN) (the "Company") today reported financial results for the quarter ended March 31, 2023.
  • Book value of $8.31 per share as of March 31, 2023, which includes the effects of dividends of $0.24 per share for the quarter.
  • Debt-to-equity ratio of 7.6:1 as of March 31, 2023; adjusted for unsettled purchases and sales, the debt-to-equity ratio as of March 31, 2023 was 7.5:1.
  • Cash and cash equivalents of $36.7 million as of March 31, 2023, in addition to other unencumbered assets of $7.4 million.

BIOVAXYS ACQUIRES CLINICAL STUDY MANAGEMENT COMPANY AND COMPLETES PRIVATE PLACEMENT

Retrieved on: 
Thursday, March 16, 2023

TAET provides a secure and private link for study subjects to instantly update investigators with adverse events they are experiencing onto an online database for real-time evaluation by study investigators.

Key Points: 
  • TAET provides a secure and private link for study subjects to instantly update investigators with adverse events they are experiencing onto an online database for real-time evaluation by study investigators.
  • In addition, BioVaxys is pleased to announce that it has also closed a private placement consisting of 5,360,000 common shares at a price of $0.125 per share for gross proceeds of $670,000.
  • All common shares issued pursuant to the private placement will be subject to a statutory hold period of four months and one day.
  • The Company intends to use the proceeds for the private placement of working capital.

BIOVAXYS ACQUIRES CLINICAL STUDY MANAGEMENT COMPANY AND COMPLETES PRIVATE PLACEMENT

Retrieved on: 
Thursday, March 16, 2023

TAET provides a secure and private link for study subjects to instantly update investigators with adverse events they are experiencing onto an online database for real-time evaluation by study investigators.

Key Points: 
  • TAET provides a secure and private link for study subjects to instantly update investigators with adverse events they are experiencing onto an online database for real-time evaluation by study investigators.
  • In addition, BioVaxys is pleased to announce that it has also closed a private placement consisting of 5,360,000 common shares at a price of $0.125 per share for gross proceeds of $670,000.
  • All common shares issued pursuant to the private placement will be subject to a statutory hold period of four months and one day.
  • The Company intends to use the proceeds for the private placement of working capital.